AURORA-2

Hong Kong, China, August 30, 2026 Ascletis Pharma Inc. announced that the first participant has been dosed in its...

San Francisco, August 3, 2026 AusperBio Therapeutics Inc. and Ausper Biopharma Co., Ltd. announced the initiation of patient dosing...

Hong Kong – August 3, 2026 Ascletis Pharma Inc. has initiated a global Phase III clinical development program for...